Tradestie Institutional Equity Comparison Engine

DRTS vs CRMD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRMD Overall Edge

CRMD Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while DRTS counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DRTS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CRMD at 29.5x Forward P/E and 41.0% operating margin (-47.7% YoY). In options structure, DRTS sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against CRMD sits in BREAKDOWN (90th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRMD
DRTS N/M vs CRMD 29.5x Fwd P/E
Growth & Margin Winner CRMD
Op Margin 0.0% vs 41.0% ยท YoY +0.0% vs -47.7%
Momentum & Technical Winner DRTS
1Y +225.5% vs -58.5% ยท 52W Pos 70% vs 0%
Options & Structure Winner DRTS
CONSOLIDATION (18th %ile IV) vs BREAKDOWN (90th %ile IV)
DRTS NASDAQ
Alpha Tau Medical Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$12.09
+1.0% 1D
Market Cap $1.2B
1M Return -4.2%
1Y Return +225.53%
Forward P/E N/M
Unified AI Score
43.3 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 71.0 Mom 60.0
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.67
-3.11% 1D
Market Cap $370.6M
1M Return -36.72%
1Y Return -58.45%
Forward P/E 29.5x
Unified AI Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DRTS +225.53% CRMD -58.45% Spread: +283.98 pp (DRTS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DRTS TTM Op. Margin: 0.0% CRMD TTM Op. Margin: 41.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRTS vs CRMD. Trailing 12-month operating profitability (DRTS 0.0% vs CRMD 41.0%) and valuation multiples (DRTS N/M vs CRMD 29.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DRTS (4) vs CRMD (6)
Institutional Metric DRTS CRMD Criterion Row Winner
Market Capitalization Scale $1.2B $370.6M Larger Scale DRTS
Trailing P/E Ratio Valuation N/M 2.4x Lower Multiple CRMD
Forward P/E Ratio Valuation N/M 29.5x Lower Multiple CRMD
Revenue Growth (YoY) Growth +0.0% -47.7% Higher Growth DRTS
Operating Margin (TTM) Profitability 0.0% 41.0% Higher Margin CRMD
Net Profit Margin Profitability 0.0% 15.5% Higher Margin CRMD
Return on Equity (ROE) Capital Efficiency -141.7% 15.3% Higher ROE CRMD
52-Week Range Position Momentum 70% ($3โ€“$16) 0% ($5โ€“$13) Stronger Trend DRTS
Beta / 30D Volatility Risk Regime 1.71ฮฒ ยท 62% Vol 1.22ฮฒ ยท 103% Vol Lower Realized Risk DRTS
Unified Institutional Score Composite Signal 43.3 / 100 (HOLD) 55.5 / 100 (HOLD) Higher Composite CRMD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DRTS vs CRMD Buy Guide
DRTS CONSOLIDATION
95d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live DRTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 90th %ile
IV Regime Extreme (>80th %ile)
Live CRMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DRTS nor CRMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.